



The Medicines Patent Pool Foundation

Governance Board Meeting Chairman's Summary

3 December 2013
Teleconference

Attendees: Charles Clift (Chair), Sigrun Møgedal, Bernard Pécoul, Paulo Teixeira, Anna Żakowicz

Regrets: Anban Pillay

MPP Staff in Attendance: Greg Perry (Executive Director, *ex-officio* Board member), Esteban Burrone (Head of Policy), Robyn Harshaw (Operations Manager), Sandeep Juneja (Business Development Director), Chan Park (General Counsel)

The Governance Board of the Medicines Patent Pool (MPP) thanks the Expert Advisory Group (EAG) for its report assessing the final results of negotiations between the MPP and Bristol-Myers Squibb (BMS). The Board has reviewed the EAG report and the proposed Licence and Technology Transfer Agreement between the MPP and BMS. The Board agrees with the EAG's assessment that the proposed collaboration is consistent with the MPP's mandate as defined in its Statutes and Memorandum of Understanding with UNITAID, and represents a significant improvement over the *status quo*. Therefore, the Board requests the Executive Director to finalise and sign the necessary documents with BMS to formalise the collaboration. The Board further recommends that the MPP continue to seek the inclusion of all people living with HIV in low- and middle-income countries in this and other future collaborations.